fda warning letter semaglutide october 2025 Sends Letters to More Than 50 GLP-1 Compounders and Manufacturers FDA warns companies over unapproved

In addition, it will be interesting to distinguish between UPS-dependent and UPS-independent anticancer activities of copper complexes

The fact that covering GLP-1s under Medicare Part D for authorized uses is already making a mark on total Part D program spending could be a sign of even higher spending to come as Part D plans are now able to cover Wegovy for its heart health benefits, as other uses for GLP-1s are approved, and as policymakers consider legislation that would authorize Medicare to cover obesity drugs

Most users tolerate it well, especially with gradual dose escalation

Obesity and diabetes: an update

This is particularly relevant for medications with narrow therapeutic windows like blood thinners, seizure medications, and certain antibiotics